Publications & References

Recent Publications and Media
NOVEMBER 02, 2021Restoring the Extracellular Matrix: A Neuroprotective Role for Collagen Mimetic Peptides in Experimental Glaucoma

Optic neuropathies are a major cause of visual disabilities worldwide, causing irreversible vision loss through the degeneration of retinal ganglion cell (RGC) axons, which comprise…

Read More >
Scientific References

Corneal Collagen as a Potential Therapeutic Target in Dry Eye Disease. R.O. Baratta, E. Schlumpf, B.J. DelBuono, S. De Lorey, and D.J. Calkins.  (2021) Survey of Ophthalmology May/June.
DOI: 10.1016/j.survophthal.2021.04.006

– – – – – – – – –

Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration.  R.O. Baratta, B. J. Del Buono, E. Schlumpf,  B.Ceresa, and D.J. Calkins.  Frontiers in Pharmacology 2021 (12) 1-8.

View All References

Industry Era 10 Most Inspiring CEOs of 2021
OCTOBER 03, 2021Industry Era 10 Most Inspiring CEOs of 2021 Honoring Eric Schlumpf

Eric Schlumpf, President & CEO of Stuart Therapeutics, has extensive experience leading early-stage companies in various industries.

Read More >
AUGUST 11, 2021Discovering the Therapeutic Power of Collagen with Eric Schlumpf

Eric Schlumpf, president and CEO of Stuart Therapeutics, took a winding path to launch his South Florida-based eye-care company. Along the way, he met academic researchers…

Listen To The Podcast >
Discovering the Therapeutics Power of Collagen
AUGUST 16, 2021Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration

The cornea of the eye is at risk for injury through constant exposure to the extraocular environment. A highly collagenous structure, the cornea contains several different types distributed across multiple layers. The anterior-most layer contains…

Read More >

Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents through license. At Stuart Therapeutics, we are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications. We are interested in strategic partner relationships that will extend and accelerate our impact.